tetano
Editor, Senior Moderator
J Infect Dis. 2012 May 2. [Epub ahead of print]
Th1 Cells Elicited by H5N1 Vaccination Predict Seroprotection.
Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana R, Goudsmit J, Cox RJ.
Source
The Gade Institute, University of Bergen, N-5021 Bergen, Norway.
Abstract
BackgroundVaccination is the best measure to protect the population against a potential H5N1 pandemic, but two doses of vaccine are needed to elicit protective immune responses. An immunological marker for H5N1 vaccine effectiveness is needed for early identification of the best vaccine candidate.MethodsWe conducted a phase I clinical trial of a virosomal H5N1 vaccine adjuvanted with Matrix M(TM) (ClinicalTrials.gov, NCT00868218, http://clinicaltrials.gov/ct2/show/NCT00868218?term=nct00868218&rank=1). Sixty adult volunteers were vaccinated intramuscularly with two doses of either 30?g haemagglutinin (HA) alone or 1.5, 7.5 or 30?g HA and Matrix M(TM) adjuvant (50?g). The humoral response was measured by the haemagglutination inhibition (HI), microneutralisation (MN) and single radial haemolysis(SRH) assays and the CD4(+) T helper 1 (Th1)-response by intracellular staining for the cytokines IL-2, IFN-γ and TNF-α.ResultsThe adjuvanted vaccine effectively induced CD4(+) Th1-cell responses and the frequency of influenza-specific Th1-cells after the first vaccine dose predicted subsequent HI, MN and SRH seroprotective responses after the second vaccination.ConclusionsThese results support early identification of Th1-cell responses as a predictive biomarker for an efficient vaccine response, which could have great implications for early identification of vaccine low- or non-responders when evaluating future pandemic influenza vaccines.
PMID:
22551811
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22551811
Th1 Cells Elicited by H5N1 Vaccination Predict Seroprotection.
Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana R, Goudsmit J, Cox RJ.
Source
The Gade Institute, University of Bergen, N-5021 Bergen, Norway.
Abstract
BackgroundVaccination is the best measure to protect the population against a potential H5N1 pandemic, but two doses of vaccine are needed to elicit protective immune responses. An immunological marker for H5N1 vaccine effectiveness is needed for early identification of the best vaccine candidate.MethodsWe conducted a phase I clinical trial of a virosomal H5N1 vaccine adjuvanted with Matrix M(TM) (ClinicalTrials.gov, NCT00868218, http://clinicaltrials.gov/ct2/show/NCT00868218?term=nct00868218&rank=1). Sixty adult volunteers were vaccinated intramuscularly with two doses of either 30?g haemagglutinin (HA) alone or 1.5, 7.5 or 30?g HA and Matrix M(TM) adjuvant (50?g). The humoral response was measured by the haemagglutination inhibition (HI), microneutralisation (MN) and single radial haemolysis(SRH) assays and the CD4(+) T helper 1 (Th1)-response by intracellular staining for the cytokines IL-2, IFN-γ and TNF-α.ResultsThe adjuvanted vaccine effectively induced CD4(+) Th1-cell responses and the frequency of influenza-specific Th1-cells after the first vaccine dose predicted subsequent HI, MN and SRH seroprotective responses after the second vaccination.ConclusionsThese results support early identification of Th1-cell responses as a predictive biomarker for an efficient vaccine response, which could have great implications for early identification of vaccine low- or non-responders when evaluating future pandemic influenza vaccines.
PMID:
22551811
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22551811